Truist Securities Reiterates Buy on Edgewise Therapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Srikripa Devarakonda has reiterated a Buy rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $25 price target.
June 27, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $25 price target.
The Buy rating and maintained price target by Truist Securities analyst Srikripa Devarakonda indicates a positive outlook for Edgewise Therapeutics in the short term. This news is directly related to EWTX and is important for investors as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100